Edition:
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

251.00DKK
22 Jul 2016
Change (% chg)

-- (--)
Prev Close
kr.251.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
198,154
52-wk High
kr.361.00
52-wk Low
kr.197.00

BAVA.CO

Chart for BAVA.CO

About

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate... (more)

Overall

Beta: 1.40
Market Cap(Mil.): kr.7,762.98
Shares Outstanding(Mil.): 30.93
Dividend: --
Yield (%): --

Financials

  BAVA.CO Industry Sector
P/E (TTM): -- 36.15 37.05
EPS (TTM): -4.03 -- --
ROI: -8.86 15.11 14.35
ROE: -9.25 16.17 15.56

BRIEF-Bavarian Nordic: Expansion of IMVAMUNE orders from Canada

* Announces expansion of IMVAMUNE orders from Canadian government

Jun 15 2016

BRIEF-Bavarian Nordic: Positive results from Phase 1 Trial of broad spectrum RSV vaccine

* Announces positive top line results from a Phase 1 Trial of a novel, broad spectrum RSV vaccine in healthy adult and elderly populations

May 23 2016

BRIEF-Bavarian Nordic signs $100 million contract for IMVAMUNE in USA

* Announces $100 million supply contract for IMVAMUNE Smallpox Vaccine with the U.S. Government

May 19 2016

BRIEF-Bavarian Nordic Q1 EBIT loss increases to DKK 153 million

* Q1 revenue 23 million Danish crowns ($3.52 million) versus 235 million crowns year ago

May 13 2016

BRIEF-Bavarian Nordic: Positive data for Ebola vaccine regimen

* Said on Tuesday results of Phase 1 study of a preventive Ebola vaccine regimen suggest that regimen was well-tolerated by healthy volunteers and did not result in any vaccine-related serious adverse events

Apr 20 2016

CORRECTED-BRIEF-Bavarian Nordic to raise up to DKK 665 mln in private placement

* Said on Wednesday resolved to launch an offering of up to 2.8 million shares

Apr 14 2016

BRIEF-Bavarian Nordic FY EBIT decreases to DKK 1.6 million

* FY revenue 1.02 billion Danish crowns versus 1.22 billion crowns year ago

Mar 07 2016

BRIEF-Bavarian Nordic enters research collaboration to develop MRSA vaccine

* Entered into a joint collaboration with Evaxion Biotech and Technical University of Denmark for development of an MVA-BN-based vaccine against MRSA

Feb 04 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : GlobalData
$300.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.